For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
TB4 (full 43-AA) is an endogenous actin-binding peptide with genuine Phase 2 clinical evidence in ophthalmology and wound healing. TB-500 is a synthetic 7-AA fragment with no human trial data. The most sought-after application (musculoskeletal repair) has zero human evidence for either compound. TB-500 was FDA de-listed in September 2024. Both are WADA banned.
TB4 refers to the full-length 43-amino-acid peptide produced naturally in the human body. TB-500 refers to a synthesized peptide fragment containing only 7 amino acids from the TB4 sequence (positions 17 to 23), the actin-binding site region. While their mechanisms are partially shared, TB4 has substantially more clinical evidence than the synthesized fragment. There are NO human clinical trials for TB-500 specifically. All human trial data pertains to full-length TB4. This profile covers both, clearly distinguishing when evidence applies to the full peptide versus the fragment.
TB-500 was de-listed as a compoundable drug by the FDA in September 2024. Both TB4 and TB-500 are banned by WADA across all competitive sports. Researchers must be aware of these regulatory dimensions before interpreting any evidence in this profile.
Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide found in virtually all tissues of the human body, with particularly high expression in platelets, macrophages, the thymus, spleen, brain, liver, kidney, testis, myocardium, and leukocytes. It is one of the most abundant intracellular peptides in eukaryotic cells and plays a fundamental role in actin cytoskeleton regulation, the dynamic protein scaffolding network that governs cell shape, movement, and architecture.
After tissue injury, Tβ4 is rapidly released by platelets, macrophages, and many other cell types to protect cells from further damage and coordinate the repair response. Its core function is sequestering G-actin (globular actin monomers), which regulates actin filament polymerization and thereby controls cell migration, proliferation, and differentiation. This makes Tβ4 a fundamental coordinator of the wound healing response at the cellular architecture level.
TB-500 is the synthetic replication of the active actin-binding fragment of Tβ4, specifically amino acids 17 to 23 (the sequence Ac-LKKTETQ). This 7-amino acid region contains the core actin-binding domain responsible for triggering angiogenesis and hair follicle activation. Its pharmaceutical development has been driven by the hypothesis that this fragment captures the most therapeutically relevant activity of the full peptide in a smaller, more synthetically tractable molecule.
The clinical development of TB4 has been pursued primarily by RegeneRx Biopharmaceuticals under the trade name RGN-259 (ophthalmic formulation). The compound has completed multiple Phase 2 clinical trials and is in or preparing for Phase 3 development in ophthalmology, making ophthalmic healing the most clinically advanced application.
TB4's mechanism centers on actin cytoskeleton regulation, the dynamic protein scaffolding network that determines cell shape, movement, and architecture. The key interaction is with G-actin (globular actin monomers): TB4 sequesters free G-actin by binding it at a 1:1 ratio, regulating the pool of actin available for polymerization into F-actin filaments. By controlling this balance, TB4 governs whether cells extend migration-driving protrusions (lamellipodia, filopodia), whether they contract, and whether they divide.
In the context of injury, this actin regulation translates into coordinated repair: endothelial cells migrate toward wounds and form new blood vessels (angiogenesis); epithelial cells migrate to cover denuded surfaces (re-epithelialization); and stem and progenitor cells are mobilized from bone marrow and tissue niches to regenerate damaged structures. Tβ4 also decreases the number of myofibroblasts in wounds, the cells responsible for contractile scar formation, resulting in reduced fibrosis and better-quality healing.
TB-500, as the synthetic aa 17 to 23 fragment, retains the core actin-binding domain activity and has shown similar tissue repair effects in preclinical models, but lacks the full signaling repertoire of the complete 43-AA molecule. This distinction is mechanistically important and directly relevant to interpreting which evidence applies to which compound.
TB4 sequesters G-actin to regulate cell migration and cytoskeletal dynamics; activates the focal adhesion kinase (FAK)/paxillin complex to drive cell survival and motility; mobilizes stem and progenitor cells for tissue regeneration; promotes angiogenesis through endothelial cell migration; and reduces myofibroblast formation to minimize scarring. TB-500 retains the actin-binding domain activity but is the fragment only.
The Phase 2 RCT by Sosne and Ousler (2015) randomized 72 subjects to 0.1% Tβ4 ophthalmic drops or placebo for 28 days in a controlled adverse environment (CAE) dry eye provocation model. While neither primary endpoint (ocular discomfort or inferior corneal staining) reached statistical significance at the exact primary timepoint, discomfort scores on day 28 were reduced by 27% in Tβ4-treated subjects versus placebo, and central and superior corneal staining showed statistically significant improvement. No adverse events were observed in any subject.
A separate Phase 2 double-blind RCT specifically in severe dry eye showed eye discomfort decreased by 35.1% in the TB4 group and corneal fluorescein staining improved by 59.1%, substantially meaningful clinical effects. Tβ4 has demonstrated efficacy across three Phase 2 clinical ophthalmic trials with zero adverse events observed in any trial, a safety-efficacy combination that is uncommon in clinical development.
TB4 significantly promotes corneal wound healing after injury, leading to the IND development of RGN-259. Full FDA approval remains pending as of 2025, with Phase 3 trials for dry eye and neurotrophic keratopathy ongoing. The 2025 Gesteira et al. paper explored engineered tandem thymosin peptides, representing next-generation optimization of the corneal application pathway.
Ophthalmology is TB4's most clinically advanced application: the most rigorous human trial design, the most consistent results across three independent Phase 2 trials, and the clearest regulatory pathway. The pattern of technically missing primary endpoints at exact timepoints while showing strong positive secondary outcomes and longer-duration effects suggests that trial design optimization (endpoint timing, patient selection) rather than mechanism failure is the key challenge. Zero adverse events across all three ophthalmic trials is a remarkable safety record. This is TB4's strongest near-term path to FDA approval.
The foundational Malinda et al. (1999) study using both topical and intraperitoneal administration demonstrated that wound healing was 42% improved compared to saline control by day four, reaching 61% improvement by day seven. After 14 days, collagen fiber bundles in treated wounds were thicker and longer with less scarring, consistent with Tβ4's known myofibroblast-reduction mechanism.
The Phase 2 pressure ulcer clinical trial (TB4) replicated these findings in humans: 42% improvement in re-epithelialization versus saline at day 4, 61% by day 7, and an 11% greater improvement in wound bed preparation in TB4-treated patients. For venous stasis ulcers, the mean healing time was 39 days with TB4 versus 71 days for placebo, a clinically significant 45% reduction in healing time, though the small study size prevented statistical confirmation.
Preclinical data in diabetic and aged mice showed significant improvement across both hydrogel and PBS formulations. Ehrlich and Hazard (2010) provided mechanistic clarity: Tβ4 reduces myofibroblast numbers in wounds, directly reducing scar formation and fibrosis, a mechanism that explains why TB4 heals wounds with better cosmetic and functional outcomes than untreated healing.
Among the strongest areas of TB4 clinical evidence outside ophthalmology. The Phase 2 wound healing data is compelling: the 39 vs. 71 day venous stasis ulcer result in particular represents a clinically meaningful and large effect size. The limitation is statistical underpowering in existing trials. Larger Phase 3 dermal wound trials are the critical next step and are scientifically well-justified. The reduction in myofibroblast formation is a mechanistically elegant feature with implications for scar reduction.
The Smart et al. (2007) Nature publication is one of the most impactful papers in TB4 research: it demonstrated that systemic TB4 administration in adult mice increased the number of capsulain-positive epicardial progenitor cells in the coronaries, atrioventricular valves, and epicardium, and crucially, this activation was independent of hypoxic injury. TB4 is capable of reactivating embryonic cardiac progenitor processes in the adult heart through systemic administration. This is the scientific basis for TB4 cardiac development.
At the cellular level, Tβ4 binds and alters cytoskeletal actin filaments in myocardial and endothelial cells, regulating migration of epicardial progenitors. It activates the focal adhesion complex, leading to Akt activation with wide-ranging effects on cell growth, survival, and motility. The Maar et al. (2021) paper confirmed that TB4 reactivates embryonic processes in the adult heart, a finding with profound implications for cardiac regenerative medicine.
The translation to humans is early-stage. The Zhu et al. (2016) pilot study in acute STEMI patients used autologous endothelial progenitor cells pre-treated with Tβ4 before transplantation, rather than TB4 directly. It reported favorable safety outcomes and represents one of the first human attempts to leverage Tβ4's progenitor mobilization for cardiac repair.
One of the most scientifically exciting application areas in TB4 research, anchored by a landmark Nature publication. However, the human evidence is extremely early: a single pilot safety/feasibility study that used TB4-treated progenitor cells rather than direct TB4 administration. The gap between compelling preclinical biology and validated human outcomes is wide. Well-designed cardiac RCTs using direct TB4 administration are urgently needed to determine whether the extraordinary preclinical results can be translated.
Zhang et al. reported that Tβ4 treatment markedly inhibited the TGFβ1/NF-κB signaling pathway in TBI models, affecting both neuroprotection (limiting acute injury) and neurorestoration (promoting recovery). In the experimental autoencephalomyelitis mouse MS model, TB-500 treatment produced functional neurological improvement, the starting point for studying its use in MS patients. Morris et al. (2010) demonstrated improved functional neurological outcomes in a rat embolic stroke model.
The neuroprotective mechanisms operate through multiple potential pathways: modulation of CNS inflammatory responses, promotion of neuronal survival via Akt activation, and enhancement of axonal regeneration and synaptic plasticity through actin cytoskeletal regulation (actin dynamics are fundamental to axonal growth cones and dendritic spine remodeling). The mechanism is credible.
Mechanistically credible: actin dynamics are fundamental to synaptic plasticity and axonal growth. But the human evidence is entirely absent. All neuroprotection findings are preclinical. No human neurology trials exist for TB4 or TB-500 in any CNS indication. This remains a promising but very early-stage application area requiring substantial additional preclinical work followed by first-in-human CNS safety studies before therapeutic conclusions can be drawn.
In a 6-month study, thymosin beta-4 administration improved skeletal muscle fiber regeneration in dystrophin-deficient mice, a model of Duchenne muscular dystrophy. In rat incision wound models, TB-500-treated animals showed minimal scarring and significantly narrower wounds compared to controls. In tendon and ligament pathology, both BPC-157 and TB-500 have shown remarkable efficacy in preclinical models of tissue repair.
The mechanism is well-characterized: TB4 promotes tendon healing by enhancing tendon outgrowth, improving cell survival, and stimulating cell migration through FAK/paxillin and actin remodeling pathways. The compound also modulates growth factors including FGF (fibroblast growth factor) and VEGF (vascular endothelial growth factor), supporting the vascularization of healing tendon tissue that is critical for long-term repair quality.
The preclinical data in musculoskeletal repair is consistent and robust across multiple tissue types and independent research groups. This is the most clinically sought-after application for TB-500 specifically, driven by the sports medicine and athletic performance community. However, no dedicated human musculoskeletal trials exist for either TB4 or TB-500. The gap between animal models and validated human evidence remains entirely uncrossed. This is the most significant disconnect between clinical demand and clinical evidence in the entire TB4/TB-500 research landscape.
The active fragment encoded by amino acids 17 to 23 of Tβ4, which is exactly the sequence replicated by TB-500, triggers angiogenesis and growth of hair follicles. The Gao et al. (2015) study demonstrated that exogenous Tβ4 induced the transition of hair follicles from the resting telogen phase into the active anagen (growth) phase in mice. The mechanism involves improved follicular vascularization and the mobilization of stem cells in the hair follicle bulge region.
Intriguing biological mechanism, follicular vascularization and stem cell mobilization, but evidence is limited to a single mouse study with no independent replication. No human hair growth trials exist for TB4 or TB-500. This is the weakest use case from an evidence perspective and should be characterized as speculative in the absence of human data.
Chen et al. demonstrated that Tβ4 reduced TGF-β1, TGFβR II, Smad2, and Smad3 expression in liver tissue in a bile duct ligation cholestatic fibrosis model, and reduced TGFβR II expression in human hepatic stellate cells, directly implicating the TGFβ/Smad signaling pathway (the master regulator of fibrosis) as Tβ4's anti-fibrotic mechanism.
The correlational human data is noteworthy: Tβ4 levels were negatively correlated with both inflammation and fibrosis scores in patients with chronic hepatitis B combined with NAFLD, and Tβ4 expression in serum and liver tissue was negatively correlated with TNF-α. This is not interventional evidence but provides biological plausibility in human disease tissue.
Strong mechanistic rationale: TGFβ/Smad inhibition is one of the most validated anti-fibrotic mechanisms in biology, and the correlational human data adds biological plausibility. No interventional human trials yet. Anti-fibrotic applications represent an important and clinically high-priority area given the enormous unmet need in liver fibrosis, NAFLD/NASH, and renal fibrosis. TB4's anti-fibrotic mechanism via actin regulation of stellate cell activation is distinct from most anti-fibrotic drug approaches.
In the autoencephalomyelitis (EAE) mouse model, TB-500 treatment produced notable improvements in neurological function, suggesting potential relevance to multiple sclerosis. TB4's anti-inflammatory properties, reducing inflammatory mediator expression, modulating NF-κB signaling, and suppressing myofibroblast activation, provide a mechanistic basis for applications in autoimmune and inflammatory conditions more broadly.
Hypothesis-generating preclinical data only. No human autoimmune trial results for TB-500 or TB4 have been published. The mechanistic rationale is sound: actin remodeling and myofibroblast suppression are relevant to multiple inflammatory conditions. But this remains entirely uncharacterized in human disease contexts.
Thymosin Beta-4 improved mortality when administered intravenously to septic rats, decreasing inflammatory mediators, lowering ROS levels, upregulating anti-oxidative and anti-apoptotic enzymes, and suppressing pro-inflammatory TLR signaling. Tβ4 levels are negatively correlated with endotoxemia in clinical observations.
For comparative context: Thymosin Alpha-1 has a large Phase 3 sepsis trial (TESTS, n=1,106) and extensive meta-analytic data. TB4/TB-500 is far behind Tα1 in this application and cannot reasonably compete with it as a sepsis research candidate without substantial additional development.
Preclinical signal only. No human sepsis trials for TB4 or TB-500. This application is mechanistically plausible but represents one of the least developed areas of TB4 research, and it is overshadowed by Thymosin Alpha-1's far more extensive clinical data in the same indication.
Loading: 2-5mg 2x/week for 4-6 weeks. Maintenance: 2-2.5mg 1x/week.
Critical regulatory context: TB-500 was de-listed by the FDA as a compoundable drug in September 2024 and cannot be legally compounded for human use in the USA. Both TB4 and TB-500 are WADA Prohibited across all competitive sports. Any athlete subject to doping control must not use either compound. No formal pharmacokinetic study has been published for either TB4 or TB-500 by any administration route, the most significant data gap in the entire development program. Research-grade quality standards: HPLC purity 98% or above, full 43-AA sequence confirmation for TB4 by mass spec, TB-500 sequence verification confirming Ac-LKKTETQ with acetylated N-terminus, endotoxin below 1 EU/mg for injectable preparations.
TB4/TB-500 vs. BPC-157 (Tissue Repair): These two compounds are the most commonly paired in research community discussions and are both primarily sought for musculoskeletal repair. They operate through distinct and complementary mechanisms: TB4/TB-500 works through actin cytoskeletal regulation, FAK/paxillin signaling, and stem/progenitor cell mobilization; BPC-157 works through VEGFR2-driven angiogenesis, the NO system, and growth hormone receptor upregulation. Neither has validated human musculoskeletal trial data. In terms of regulatory standing, TB-500 is in a more restricted position than BPC-157: FDA de-listed and WADA banned, versus BPC-157's FDA Category 2 status.
TB4/TB-500 vs. Thymosin Alpha-1 (Namesake Comparison): The name Thymosin creates a common misconception that TB4 (Thymosin Beta-4) and Tα1 (Thymosin Alpha-1) are related compounds. They are not. They were isolated from the same thymic extract but are structurally and mechanistically unrelated. Tα1 is an immune modulator operating through TLR signaling on dendritic cells. TB4 is an actin cytoskeleton regulator operating through G-actin sequestration in virtually all cell types. They do not share mechanism, target, or indication overlap. Tα1 has far stronger human evidence (30+ trials, 11,000+ subjects) and global regulatory approvals.
The most informative human safety data for TB4 comes from a dedicated Phase 1 randomized controlled safety trial: 40 healthy adults received intravenously-administered doses ranging from 42 to 1,260 mg. The compound appeared well tolerated across this dose range with minimal risk for toxicity. Twenty-three non-clinical studies have additionally demonstrated safety for its current and planned uses. Rare adverse reactions reported include redness and pain at the injection site.
TB-500 was de-listed as a compoundable drug by the FDA in September 2024, and both TB4 and TB-500 are banned by WADA. The safety data that exists applies to pharmaceutical-grade TB4 in clinical settings, not to TB-500 fragments from unregulated research peptide suppliers, which carry the standard impurity and immunogenicity risks associated with unverified compounding.
No absolute contraindications have been established. Regulatory and WADA status are the primary cautions: any athlete subject to anti-doping testing must not use either compound. Researchers should verify current regulatory status before initiating any human use.
TB4/TB-500 occupies a unique and somewhat complicated position in the research landscape. TB4 (full-length) has genuine Phase 2 clinical evidence in ophthalmology and wound healing, real, human, controlled data with meaningful effect sizes. The ophthalmic application through RegeneRx has the clearest clinical development pathway.
TB-500 as the synthetic fragment has no human clinical trial data of its own, and the de-listing by the FDA in 2024 and WADA prohibition complicate access and research legitimacy. The defining tension in this profile is the enormous gap between the most sought-after application (musculoskeletal and tendon repair in sports medicine) and the near-total absence of human evidence for it.
The preclinical tissue repair data is compelling and internally consistent, but compelling preclinical evidence describes many compounds that have ultimately failed in human trials. Well-designed human musculoskeletal trials would be transformative for this compound's clinical standing.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use